Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
A legal spat that includes South San Francisco biotech giant Genentech has the potential to cost patients who need several drug treatments, including a handful for cancer treatment. Citing derelict royalty payments on several drug treatments — including three for cancer — Nevada-based PDL BioPharma filed a notice of arbitration earlier this month against Genentech. The suit stems from a 2003 agreement that the two companies made over a patent dispute, which required Genentech to pay licensing fees to use PDL's medical technologies. Genentech has oft been touted as a leader in cancer treatment, creating antibody drugs that strike tumors while causing minimal damage to surrounding tissue. Its sought-after drug Herceptin, which fights metastatic breast tumors, is one of the drugs affected by the suit.
Help employers find you! Check out all the jobs and post your resume.
A legal spat that includes South San Francisco biotech giant Genentech has the potential to cost patients who need several drug treatments, including a handful for cancer treatment. Citing derelict royalty payments on several drug treatments — including three for cancer — Nevada-based PDL BioPharma filed a notice of arbitration earlier this month against Genentech. The suit stems from a 2003 agreement that the two companies made over a patent dispute, which required Genentech to pay licensing fees to use PDL's medical technologies. Genentech has oft been touted as a leader in cancer treatment, creating antibody drugs that strike tumors while causing minimal damage to surrounding tissue. Its sought-after drug Herceptin, which fights metastatic breast tumors, is one of the drugs affected by the suit.
Help employers find you! Check out all the jobs and post your resume.
